摘要
局部晚期头颈部鳞状细胞癌需要采用多学科治疗的方法,包括手术+放疗、伴或不伴化疗以及同步放化疗.诱导化疗目前仍存在争议.靶向药物西妥昔单抗已在头颈部鳞状细胞癌的治疗中取得满意的效果.针对程序性死亡蛋白-1及其配体的抑制剂也显示出显著的功效,然而,只有少数患者可以从单药治疗中受益.为提高免疫疗效,联合免疫治疗成为可选策略.
Locally advanced head and neck squamous cell carcinoma requires a multidisciplinary approach,including surgery followed by radiotherapy,with or without chemotherapy,or definitive concurrent chemoradiotherapy.The application of induction chemotherapy remains controversial.Cetuximab has achieved satisfactory results in the treatment of head and neck squamous cell carcinoma.Immunocheckpoint inhibitors against the receptor programmed death-1(PD-1)and programmed death ligand-1(PD-L1)have demonstrated clinical efficacy in head and neck squamous carcinoma.However,only a small subset of patients can benefit from anti-PD-1 and anti-PD-L1 monotherapy.To improve the effectiveness of immunotherapy,combined of immunotherapy and other treatments has become an alternative strategy.
作者
臧守梅
严丹方
严森祥
Zang Shoumei;Yan Danfang;Yan Senxiang(Department of Radiotherapy,First Affiliated Hospital,Zhejiang University,Hangzhou 310000,China)
出处
《国际肿瘤学杂志》
CAS
2019年第12期741-744,共4页
Journal of International Oncology
